siRNA targeting survivin
AssigneeDharmacon, Inc.
InventorsAnastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
Life of this patent
Estimating the term…
Abstract
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
Claims20
An siRNA molecule, wherein said siRNA molecule consists of:
- (a) a duplex region, wherein said duplex region consists of a sense region and an antisense region, wherein said sense region and said antisense region are each 19-30 bases in length and said antisense region comprises a sequence that is the complement of SEQ ID NO:
- 451 or SEQ ID NO:
- 452;
- and (b) either no overhang regions or at least one overhang region, wherein each overhang region has six or fewer bases.
A chemically synthesized double stranded siRNA molecule, wherein:
- (a) each strand of said double stranded siRNA molecule is between 19 and 30 nucleotides in length;
- and
- (b) one strand of said double stranded siRNA molecule comprises a sequence that is the complement of SEQ ID NO:
- 451 or SEQ ID NO:
- 452.
A pool of at least two siRNAs, wherein said pool comprises a first siRNA and a second siRNA, wherein said first siRNA consists of a duplex region of 19-30 base pairs that has a first antisense region that comprises a sequence that is complementary to SEQ ID NO:
- 451 and either no overhang regions or at least one overhang region, wherein each overhang region has six or fewer nucleotides;
- and said second siRNA consists of a duplex region of 19-30 base pairs that has a second antisense region that comprises a sequence that is complementary to SEQ ID NO:
- 452 and either no overhang regions or at least one overhang region, wherein each overhang region has six or fewer nucleotides.
Dependencies are inferred from the claim text.